Glucocorticoids and fludarabine are able to induce typical features of apoptosis in CLL lymphocytes. Cysteinyl aspartate specific proteases (caspases) play a key biochemical role in the apoptotic pathway. Caspase activation following cytotoxic stimuli leads to highly specific proteolytic cleavage of functionally important cellular enzymes. One of them is poly ADPribose) polymerase (PARP). To some extent caspase activation seems to be under the control of the Bcl-2 family of interacting proteins. We determined the role of Bcl-2-family proteins Bcl-2 (anti-apoptotic) and Bax (pro-apoptotic), activation of caspase-3 (CPP32/Yama) and activation of PARP in CLL apoptosis. All 21 analyzed CLL samples expressed Bcl-2 and Bax. Four of 13 (31%) samples with a low Bcl-2/Bax ratio exhibited in vitro prednisolone resistance, whereas eight of nine (88%) samples with a high Bcl-2/Bax ratio were in vitro resistant (р0.025). There was no significant correlation between clinical pre-treatment status and Bcl-2/Bax ratio. Caspase-3/CPP32 activity increase was registered after dexamethasone as well as after fludarabine treatment in CLL lymphocytes in vitro. Caspase inhibitor Z-VAD.fmk was only able to partially block dexamethasone-induced and spontaneous apoptosis but not fludarabine-induced apoptosis in CLL lymphocytes. PARP activity decreased after dexamethasone and fludarabine treatment. PARP inhibitor 3-aminobenzamide (3-AB) was able to partially inhibit dexamethasone-induced apoptosis but not fludarabineinduced and spontaneous apoptosis.
Introduction
B chronic lymphocytic leukemia (B-CLL) is an accumulative disease of B lymphocytes arrested in G 0 phase of the cell cycle. The pathophysiological causes of the G 0 accumulation and extended survival of lymphocytes in B-CLL are not well understood. 1, 2 One hypothesis is that extended survival is based on an inadequate/disturbed ability to undergo apoptosis. 1, 2 High rates of spontaneous apoptosis are a very common observation in freshly cultured B-CLL cells ex vivo. [3] [4] [5] This is possibly triggered by the absence of as yet uncharacterized in vivo survival factors. 2 Several drugs used in clinical CLL therapy, such as glucocorticoids, 5 chlorambucil, 6 2-chloro-2-deoxyadenosine 7-10 and fludarabine 11 are able to induce programmed cell death in CLL lymphocytes in vitro. A significant correlation between ex vivo induction of apoptosis in CLL cells and clinical response to the ex vivo used drugs has been reported. 5, 6 Various pro-apoptotic stimuli including genotoxic damage, cytotoxic stress and glucocorticoids result in the activation of caspases, which mediate highly specific proteolytic cleavage events in the apoptotic dying cell. relevant caspase target. 13 The caspase activation mechanism seems to be at least partially under the control of the Bcl-2 family of dimerizing proteins. 12 In this study we determined the association of Bcl-2 and Bax expression and response to ex vivo glucocorticoid therapy in CLL. Furthermore, we examined the role of caspase-3 and PARP activation in dexamethasone and fludarabine-induced apoptosis in CLL.
Proteolytic cleavage of functionally essential cellular key enzymes plays a central role in the biological pathway of apoptosis.
14 At the heart of the proteolytic pathway acts a family of cysteinyl aspartate-specific proteinases, the caspases. 12, [15] [16] [17] Members of the caspase family are cyteinyl proteases with a strong affinity to aspartic acid that are highly homologous to C. elegans protein Ced-3 and human interleukin-1␤ converting enzyme (ICE). 18 Caspases have been grouped into at least two subfamilies (ICE and CED-3). 12, 18 Members of the CED-3 subfamily (Caspases-2, -3, -8 and 10) are largely involved in apoptosis. 12 To date, several caspases have been identified (eg ICE, CPP32, FLICE, MCh2, MCh3). One of the best characterized caspases is caspase-3 (CPP32/Apopain/Yama).
14 All family members are synthesized as proenzymes that are processed at Asp-x sides to generate heterodimeric mature active enzymes. 12 For some caspases autoactivation has been described. 12, 19, 20 The distinct cleavage patterns made it possible to generate specific inhibitory aldehyde-or ketone-conjugated peptides. 17 A discrete number of specific proteins appear to be targeted by caspases once the cell-death pathway has been initiated. Several of these enzymes have been identified. Caspase substrates include enzymes that are involved in genome function such as PARP, 13, 21 DNA-dependent protein kinase 22 and the 70-kDa protein component of the U1 small ribonucleoprotein 23 regulators of cell cycle progression, including the retinoblastoma gene product 24 and protein kinase C 25 and structural proteins such as laminins 26 and actin. 20 The major effects of these cleavage events are a halt in cell cycle progression, disabling of homeostatic and repair mechanisms and a dissembling of structural components. 20 Multiple activation mechanisms feed into this common cell death pathway. Several proapoptotic stimuli such as CD-95 activation, 19, 27 cytostatic drugs 28, 29 and glucocorticoids 30 have been identified to cause caspase activation.
In this study we determined the role of caspase-3 (CPP32) activation in corticoid and fludarabine-induced apoptosis in CLL lymphocytes.
One major caspase-3 target is PARP. 12, 13 PARP is a 116-kDa polypeptide that physiologically converts NAD to nicotinamide and protein-linked ADP-ribose polymers. 21, 31, 32 PARP is relatively inactive in unperturbed cell culture cells 21 but PARP activation follows, for example, DNA strand break inducing agents. Consecutively PARP activation contributes to cellular NAD depletion which is a typical event in the course of apoptosis. [33] [34] [35] On the other hand, is specific PARP cleavage with the appearance of a characteristically 85-89-kDa fragment a typical sign of caspase activation during pro-grammed cell death? 13, 16, 21, 36 3-Aminobenzamide (3-AB), an inhibitor of PARP and other NAD-requiring enzymes is able to delay apoptosis in several cell systems. 37 The role of PARP activation, cleavage and consecutive inactivation in druginduced apoptosis is still not totally clear. We examined PARP activity changes following treatment with dexamethasone and fludarabine in CLL. In parallel, PARP cleavage was monitored by Western blot analysis.
Proteins from the Bcl-2 gene family play an important role in the regulation of programmed cell death. Among multiple genes that are involved in the regulation of programmed cell death (PCD), Bcl-2 stands out for its ability to block apoptosis. [38] [39] [40] The Bcl-2 gene product is a 26-kDa 239-amino acid integral membrane protein which is located at the mitochondrial, nuclear and cell membrane and the endoplasmatic reticulum. 6 Independently of t(14;18) translocation, Bcl-2 deregulation was observed in several hematological malignancies 41, 42 including CLL. 2 Caspase activation seems to be partially under control of Bcl-2-family proteins. For this reason we additionally determined Bcl-2 and Bax expression in CLL. Bcl-2 is functionally interacting with other structurally related proteins. It forms heterodimers with several other proteins from the Bcl-2 family. One of them is Bax, which shares 21% of amino acid identity with Bcl-2. 43 Bax is a strong promoter of programmed cell death. The interaction of Bcl-2 and Bax represents a crucial point of the PCD pathway. When Bcl-2 is in excess, cells are protected. When Bax is in excess and Bax homodimers dominate, cells are susceptible to apoptosis.
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Patients and methods
Patients
All patients were treated at the department of Haematology and Oncology, Klinikum Grosshadern. CLL was diagnosed according to standard clinical and laboratory data. Treated and untreated patients were included. The last treatment period was at least 8 weeks ago. Treatment regimens for pretreated patients were either chlorambucil/prednisolone and/or fludarabine monotherapy.
Reagents
Fludarabine (Schering-AG, Berlin, Germany) was dissolved in 100% dimethylsulfoxide (DMSO) for a stock solution of 10 mM. Dexamethasone was obtained from Merck KG (Darmstadt, Germany), and prednisolone was from Hoechst AG (Frankfurt, Germany) .
Caspase inhibitor tripeptide Z-VAD.fmk (N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone) was purchased from Bachem Biochemicals (Bubendorf, Switzerland). Fluorogenic substrate DEVD-AFC (N-acetyl-Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl coumarin) was purchased from Biomol Feinchemikalien (Hamburg, Germany). All peptides were stored as stock solutions in DMF.
3-Aminobenzamide (3-AB) was purchased from Sigma Biochemicals (Muenchen, Germany).
Isolation of CLL cells
Peripheral blood samples were obtained from patients with CLL at the Medizinische Klinik III, Klinikum Grosshadern. In all cases differential blood analysis was performed in parallel and the lymphocyte proportion was over 90%. Mononuclear cells were isolated by centrifugation on a Ficoll/Hypaque gradient and then washed twice with PBS.
Cell culture conditions and drug incubations
Freshly isolated cells were cultured at a concentration of 2 × 10 6 /ml in RPMI 1640 containing 10% FCS, 10 mM Hepes, pH 7.3 and 2 mM L-glutamine. For experiments cells were washed in RPMI 1640 and then again cultured in medium with the addition of fludarabine, prednisolone or dexamethasone with or without Z-VAD.fmk or 3-AB. Fludarabine was administered at a concentration of 10 g/ml, prednisolone and dexamethasone at a concentration of 20 mol/l, Z-VAD.fmk at a concentration of 50 mol/l and 3-AB at a concentration of 3 mmol/l. Optimal drug concentrations were determined in pre-experiments.
Cellular viability
Cellular viability was determined by the WST-1 assay. 46 Cells were incubated in 96-well plates in a final volume of 100 l. After 44 h, 20 l of WST-1 dye solution (Boehringer, Mannheim, Germany) was added directly to the 96-well plates for an additional 4 h. The absorbance at 450 nm was measured using a microtiter plate ELISA reader. Cell viability was calculated as the percentage of signal in untreated control cells. Corticoid resistance was defined as the rate of living cells over 30% after 48 h.
Quantitative determination of apoptosis
Cellular viability and rate of apoptosis were simultaneously determined using Annexin-V-FLUOS and propidium iodide double staining. Apoptosis is accompanied by a loss of membrane phospholipid asymmetry, resulting in the exposure of phosphatidylserine at the surface of the cell. 47 Quantitative measurement of phosphatidylserine exposure is possible using the binding of fluorescein isothiocyanate-labeled Annexin V to phosphatidylserine. 47 For the Annexin V assay cells were incubated for 1 h at 37°C in 2 ml Annexin buffer with FITClabeled Annexin V and ethidium bromide. 47, 48 Analysis was done flow cytometrically on a FACScan (Becton Dickinson, Mountain View, CA, USA) using Lysis II software.
DNA fragmentation assay
For analysis of DNA fragmentation, cell pellets were treated with lysis buffer at 37°C overnight. Protein was then precipitated with NaCl and centrifuged at 3300 g. DNA in the supernatant was precipitated overnight with ethanol at −20°C. After centrifugation at 3300 g, the pellet was dissolved in TrisHCl/EDTA and incubated with RNase. Subsequently, electrophoresis on a 1.4% agarose gel was performed followed by ethidium bromide staining.
Western blot analysis of Bcl-2, Bax and PARP
For Western blotting, proteins obtained from whole-cell lysates were separated by 12% SDS-PAGE and transferred to ECL membranes (Amersham, Braunschweig, Germany). Probes were adjusted according to total protein content using a Biorad protein assay (Biorad, Munich, Germany). Detection of Bcl-2 was performed using a monoclonal mouse-anti-Bcl-2 antibody (Dako Glostrup, Denmark). For Bax detection a rabbit polyclonal antibody was applied (PharMingen, San Diego, CA, USA). Bound antibody was detected using the ECL chemiluminescence detection system (Amersham). Equal loading was proven by actin control staining. The tolerance range was ±10%. Films were scanned and analyzed using Pharmacia (Freiburg, Germany) image master software.
Prepared aliquoted HL-60 lysates were used as internal standard. Protein amounts (Bcl-2 res. Bax) were calculated in relation to HL-60 standard signal and given as a percentage. The Bcl-2 and Bax ratio in each case was calculated as the quotient of standard-referred Bcl-2 and Bax percentage.
Determined by the different expression of Bcl-2 and Bax in the aliquoted HL-60 standard and the different binding profiles of the antibodies used, calculated Bcl-2/Bax quotients were only relative ratios (proportionality factors) not referring to the real Bcl-2/Bax dimerising status, characterizing relative expression differences between the CLL samples examined.
PARP cleavage was assessed using the above mentioned ECL Western blot method. Therefore, monoclonal mouse antibody C-210 (Biomol, Hamburg, Germany) detecting 116-kDa PARP and a 85-kDa apoptosis relevant fragment was used.
CPP32 activity assay
Proteolytic CPP32 activity was determined fluorometrically as described by Hasegawa et al. 49 Treated cells (3 × 10 6 ) were collected, washed three times with PBS and suspended in 50 mM Tris-HCl (pH 7.4), 1 mM EDTA and 10 mM EGTA. After the addition of 10 M digitonin, cells were incubated at 37°C for 10 min. Lysates were centrifuged at 22 000 g for 3 min and cleared supernatants were collected. Protein concentrations were adjusted to 30 g/ml. Aliquots (2 ml) were incubated with 10 l of DEVD-AFC (50 mol/l) at 37°C for 15 min. The release of 7-amino-4-trifluoromethyl coumarin was monitored by a spectrofluorometer (Hitachi F-2000, Rodgau, Germany) using an excitation wavelength of 400 nm and an emission wavelength of 505 nm. Activity of controls were taken as 100%.
PARP activity assay
PARP activity was determined in permeabilized cells without stimulation with added nicked DNA as described by Berger et al. 50 Briefly, 5 × 10 5 cells were collected and washed once in hypotonic permeabilization buffer composed of 10 mM Tris (pH 7.8), 1 mM EDTA, 4 mM MgCl 2 , 10 mM DTT, 0.25 M sucrose. The cells were made permeable using 100 l of the same buffer incubated for 30 min on ice. Then, 200 l of PARP substrate mixture containing 50 mM Tris (pH 8.5), 37.5 mM MgCl 2 , 0.5 mg/ml bovine serum albumin and 50 M 3HNAD + (1.85 Bq/pmol) was added. The samples were incubated at 37°C for 25 min. The enzymatic reaction was stopped by adding 0.7 ml of 10% TCA and centrifuged for 3 min at 15 000 U/min. The pellet was washed once in 10% TCA and dissolved in 3 ml of scintillation liquid (Rotiszint, Hamburg, Germany). The sample radioactivity was measured using a Beckman TA5000 scintillation counter.
Radioactivity was calculated as the percent of radioactivity in control samples.
Results
Bcl-2 and Bax protein expression in lymphocytes from patients with CLL
Protein expression was made comparable by referring the signal to an internal standard as described above. This procedure resulted in the creation of proportionality factors.
In all 21 CLL samples Bcl-2 and Bax expression could be detected. There was a very wide range of Bcl-2 expression. Very low Bcl-2 levels (р5.0% of control) were found in five cases (24%), low Bax signals were detected in 14 samples (67%) ( Table 1 ). There was no significant correlation between Bcl-2 and Bax expression.
Correlation of in vitro drug response and pretreatment
Twelve of 21 included patients had not received any CLL treatment before. Eight patients had received corticoid and/or cytostatic drug treatment. In the pre-treated patients in vitro response rate to prednisolone was 67% (6/8) in contrast to 25% (4/12) of the patients having received therapy before. This difference was statistically significant ( 2 = 4.17, P р 0.05).
Ratio of Bcl-2/Bax protein expression, in vitro chemosensitivity and pre-treatment
Patients were grouped according to Bcl-2/Bax ratio. As cut off the mean value (12.1) was taken. In the low ratio group 31% of patients showed in vitro prednisolone resistance compared to almost 90% in the high ratio group ( Table 2 ). The discrimination was statistically significant ( 2 = 6.39, P р 0.025). In resistant cases Bax levels were also frequently elevated but relative Bax increase was lower than that of Bcl-2.
There was no relevant correlation between pre-treatment and Bcl-/Bax ratio. Nine of 12 non-pre-treated patients exhibited low Bcl-2/Bax ratios whereas four of eight in the pretreated group did.
Intraindividual changes in Bcl-2/Bax ratio and drug sensitivity in the course of time
In three cases we subsequently determined Bcl-2/Bax ratios and glucocorticoid sensitivity at different time-points. Two of these patients were untreated. In those patients repeated Bcl-2/Bax ratios and glucocorticoid sensitivity varied up to 35% res. 30%. In one case we monitored Bcl-2/Bax-levels and sensitivity before, during and after fludarabine treatment (Figure 1) . Here, glucocorticoid sensitivity increased in the surviving population during fludarabine treatment and finally decreased again. In parallel, Bcl-2/Bax ratios initially dropped and subsequently rose again. Clinically, this patient achieved a partial remission. and high (Ͼ12). As preliminary cut off (12) the arithmetic average of Bcl-2/Bax ratio was used (P р 0.025).
Ex vivo induction of oligonucleosomal DNA fragmentation in CLL patients
Fludarabine as well as prednisolone and dexamethasone were able to induce typical DNA fragmentation in CLL cells ex vivo (Figure 2 ).
Caspase-3 (CPP32) activity during drug-induced apoptosis in CLL
CPP32 proteolytic activity was measured after 24 h of treatment with dexamethasone 20 mol/l and fludarabine 10 g/ml in three CLL cases. Caspase-inhibitor Z-VAD.fmk at a concentration of 50 mol/l was added 30 min before drug treatment. CPP32 activity was increased up to 520% of control after dexamethasone treatment and up to 670% after fludarabine treatment (Figure 3 ). Pre-treatment with Z-VAD.fmk inhibited activity increase almost totally in both cases. The rate of dexamethasone-induced apoptosis was reduced by Z-VAD.fmk treatment from 30.5% to 17.8%. Toxicity of fludarabine was even slightly elevated by Z-VAD.fmk (48.5% vs 53.2%). Z-VAD.fmk treatment was also able to reduce the rate of spontaneous apoptosis from 8.9% to 4.7%.
PARP activity and PARP cleavage during druginduced apoptosis in CLL
PARP activity was monitored using a cycling method as described above. PARP activity was monitored 24 h and 48 h after starting drug incubation. For PARP determination the same samples were used as for Caspase-3 (CPP32). PARP inhibitor 3-AB was added 30 min before drug treatment. During dexamethasone treatment PARP activity initially rose to 122% of control and then decreased to 45% after 48 h (Figure 4 ). 3-AB was able to decrease PARP activity to 28% and the rate of apoptosis by 15%. In the fludarabine-treated group a continuous decrease in PARP activity was seen (86% res. 35%). 3-AB decreased PARP activity to 31% but no effect on induction of apoptosis was registered. 3-AB treatment also had no protective effect on spontaneous apoptosis but even increased the rate of PCD by 4%.
ECL Western blot analysis revealed almost complete cleavage of 116-kDa PARP 48 h after starting drug treatment with prednisolone, dexamethasone or fludarabine ( Figure 5 ).
Discussion
In this study we demonstrate that prednisolone, dexamethasone and fludarabine are able to induce apoptosis in freshly isolated CLL lymphocytes. This has been shown by others before for fludarabine and glucocorticoids. 2, 5, 51, 52 There was a significant correlation between clinical pre-treatment status and in vitro response to prednisolone.
Bcl-2 is known to promote cell survival by blocking apoptosis induced by a variety of different stimuli 39, 40 Bcl-2
Figure 1
Bcl-2/Bax ratio and ex vivo vitality in CLL cells of one patient at different points in time before, during and after four cycles of fludarabine treatment. overexpression independently from t(14;18) translocation has been described for several hematological disorders including CLL. 53, 54 The mechanisms of increased Bcl-2 expression in CLL have not been completely identified. One potential mechanism is elevated transcription following gene hypomethylation. 55 Bax (Bcl-2 associated x-protein) is a strong promoter of programmed cell death and is able to form heterodimers with Bcl-2. The equilibrium between Bcl-2 and Bax homo-and heterodimers is crucial for the susceptibility of certain cells to undergo apoptosis following distinct pro-apoptotic stimuli. 40, 43, 44 Other functionally active members of the Bcl-2 family are bcl-xS, bcl-xL, bag-1, bad and mcl-1. 45 In this study we determined whether in vitro prednisolone resistance in CLL is associated with changes in relative endogenous Bcl-2 and Bax expression. We examined 21 pretreated and non-pre-treated cases and revealed that cells with a high Bcl-2/Bax ratio seem to be more prednisolone resistant (88%) than cells with a low Bcl-2/Bax ratio (31%). Surprisingly, in resistant CLL samples not only Bcl-2 but also Bax levels were increased. However, relative increase of Bax expression was lower than that of Bcl-2. The corresponding data from the recent literature are not clear. Thomas et al 51 recently reported a statistically significant correlation between high Bcl-2/Bax ration and in vitro resistance to 9-amino-20(s)-camphtothecin and fludarabine in CLL (20 cases). Pepper et al 57, 58 showed that high Bcl-2/Bax ratios were directly related to in vitro chlorambucil resistance in CLL. McConkey et al 51 stated that ex vivo apoptosis resistance to glucocorticoid res. fludarabine and mitoxantrone was associated with elevated Bcl-2 and Bax expression.
On the other hand Begleiter et al 59 could not find any association between chlorambucil sensitivity and Bcl-2/Bax expression in CLL, and Morabito et al 60 did not see a correlation between Bcl-2 expression (alone) and in vitro resistance to chlorambucil, fludarabine and 2-CDA.
Although in this study the discrimination of in vitro resistance and sensitivity by Bcl-2/Bax quotient was statistically significant, reasonable doubt on clinical relevance and reliability of Bcl-2/Bax as predictive value still remained. There was no correlation between pre-treatment and Bcl-2/Bax ratio. This was also reported previously by others. 57 Additionally looking at the data in detail in five of 21 cases the Bcl-2/Bax ratio failed to predict in vitro response. In one case we observed in vitro sensitivity despite a very high Bcl-2/Bax ratio and four cases exhibited in vitro resistance although the Bcl-2/Bax ratio was very low.
One reason for these partially inconsistent data might be the small number of examined cases that made it impossible to stratify for other factors possibly associated with resistance (age, RAI-stage, doubling time, ␤2-microglobulin etc).
Figure 3
Proteolytic activity of caspase-3/CPP32 was measured with CPP32 fluorogenic substrate DEVD-AFC as described in Materials and methods. For caspase inhibition Z-VAD.fmk was used. The number of apoptotic cells (alive and dead) was determined by Annexin V staining. Dex, dexamethasone; Fludara, fludarabine; ZVAD, Z-VAD.fmk.
Figure 4
PARP activity was assessed using an enzymatic-cycling method as described in Materials and methods. For inhibition of PARP 3-aminobenzamide was used. The number of apoptotic cells (alive and dead) was determined by Annexin V staining. Dex. 48 h and Fludara 48 h were measured after 48 h of incubation; all others after 24 h. Dex, dexamethasone; Fludara, Fludarabine; 3-AB, 3-aminobenzamide. Additionally, Bcl-2/Bax expression in CLL cells seems not to be a static factor but subject to dynamic changes. When we examined follow-up Bcl-2 and Bax levels in treated and even in untreated patients we observed partially dramatical changes in expression ratio. There are several reports showing that chemotherapeutic agents are able to down-regulate Bcl-2 expression. 2, 61 Moreover, fludarabine and other drugs are able to induce post-transcriptional changes in Bax 56 and Bcl-2 62 which could possibly vary protein-protein interactions. In one case we observed a decrease in Bcl-2/Bax expression after fludarabine treatment. Surprisingly, prednisolone sensitivity increases after fludarabine treatment; possibly an effect of selecting clones with different resistance patterns. However, also in two untreated cases, Bcl-2/Bax expression as well as ex vivo glucocorticoid toxicity varied up to 30% at periodical controls.
Finally, we did not look at other important members of the Bcl-2 family such as bcl-xL and bcl-xS which are known to have an impact on the ability to undergo apoptosis in other models. However, to determine the definitive value of Bcl-2 and Bax as predictive factors for chemosensitivity in CLL, further studies allowing multivariate analysis of the above mentioned factors are necessary.
Furthermore, we determined in a smaller number of CLL cases the role of caspase-3 (CPP32) and PARP activity changes following ex vivo dexamethasone and fludarabine treatment.
Caspase activation and subsequent cleavage of functionally essential key enzymes play a central role in the biological processing of apoptosis apoptosis.
14 This has been demonstrated for glucocorticoids and several cytotoxic drugs. [28] [29] [30] CPP32/Yama (caspase-3) is one of the best characterized caspases and has been shown to cleave several important targets including laminins, globular actin and PARP. 30 PARP is not only an important DNA repair enzyme but also seems to play a central role for adequate NAD and ATP turnover in the course of apoptosis. 63 In this study we observed a strong increase of CPP32 activity in CLL following dexamethasone as well as fludarabine treatment. This increase in activity could be prevented by preincubation with caspase inhibitor Z-VAD.fmk. Nevertheless, cytotoxic drug effect could only be reversed in part for dexamethasone and could not be influenced for fludarabine. Possibly caspases other than CPP32, which are not efficiently inhibited by Z-VAD at a concentration of 50 mol/l, are activated after fludarabine and partially after dexamethasone treatment. Another explanation would be the existence of an alternative/parallel caspaseindependent pathway leading to apoptosis.
Spontaneous apoptosis could be blocked widely by Z-VAD.fmk. Bellosillo et al 30 reported very similar results using PARP cleavage assay as an indirect method for caspase activity measurement.
Unlike Bellosillo et al 30 we determined changes in PARP activity and additionally assessed PARP cleavage. Dexamethasone first induced a transient slight increase in PARP activity followed by a rapid decrease. Fludarabine from the beginning induced a strong PARP activity decay. 3-AB, a PARP inhibitor, was able to accelerate PARP activity decrease in both cases. However, 3-AB similarly to Z-VAD.fmk was not able to reduce fludarabine toxicity and only partially able to reverse dexamethasone-induced toxicity. Different from Z-VAD.fmk 3-AB had no protective effect on spontaneous apoptosis. Both fludarabine as well as glucocorticoids induce PARP cleavage.
Apparently in CLL different drugs employ different components of the apoptotic machinery. At least with regard to fludarabine-induced PCD caspase-3 and PARP inhibitors seem not to be able to prevent fludarabine toxicity. One reason may be the alternative activation of other caspases. Another hypothesis is that caspase-independent PCD pathways play an additional role. Preliminary data emphasize the meaning of changes in mitochondrial membrane potential, mitochondrial function and subsequently NAD utilization not only as secondary but as decisive events in the course of programmed cell death. Therefore, our next study on drug-induced apoptosis in CLL will include determination of NAD utilization, ATP content and especially mitochondrial functions.
